NCT00647244|CompletedPhase 4DMC
Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients
SWAP
Loading search results
Sponsor study identifier
Secondary identifiers
interventional
40
1 country
1
Study Start
June 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2010
Actual (reported)Study Completion
August 2010
Actual (reported)To evaluate the efficacy and safety of switching from Retrovir to Tenofovir or Abacavir in HIV-infected patients
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 26, 2008
Actual (reported)March 31, 2008
Actual (reported)June 2008
Date type not reportedThis date has not been verified as actual or estimated.
August 2010
Actual (reported)August 2010
Actual (reported)Renal function measured by Cystatin-C and creatinine clearance
Weeks 0, 4, 8, 12, 24, 24, 48, 96
Levels of renal tubule function markers in blood and urine
Weeks 0, 12, 24, 48, 96
Bone mass assessed by DEXA
Weeks 0, 24, 48, 96
Levels of bone turnover markers in blood and urine
Weeks 0, 12, 24, 48, 96
Insulin resistance
Weeks 0, 12, 24, 48, 96
Changes in body composition assessed by patient questionnaire and standardized examination by physician
Weeks 0, 12, 24, 48, 96
Patients with viral load < 40 copies/ml
Weeks 0, 4, 8, 12, 24, 48, 96
CD-4 cell count
Weeks 0, 4, 8, 12, 24, 48, 96
Fasting triglycerides, HDL and LDL
Weeks 0, 12, 24, 48, 96
Development of resistance mutations
Weeks 0, 12, 24, 48, 96
Development of adverse events and serious adverse events
Weeks 0, 4, 8, 12, 24, 48, 96
Tenofovir
Abacavir
Tenofovir disoproxil 245 mg oral tablet once daily
Abacavir 300 mg oral tablet twice daily
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Aarhus University Hospital
Århus N, 8200, Denmark
Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Ostergaard L, Langdahl BL, Laursen AL. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One. 2012;7(3):e32445. doi: 10.1371/journal.pone.0032445. Epub 2012 Mar 29.
Rasmussen TA, Tolstrup M, Melchjorsen J, Frederiksen CA, Nielsen US, Langdahl BL, Ostergaard L, Laursen AL. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis. 2011 Oct 4;11:267. doi: 10.1186/1471-2334-11-267.
40 participants (actual enrollment reported by the registry).
First Submitted
March 26, 2008
First Posted
March 31, 2008
Study Start
June 2008
Date type not reportedThis date has not been verified as actual or estimated.
Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects
Changes in subcutaneous adipose tissue assessed by DEXA
Week 0, 24, 48, 96
Contact the study team to confirm eligibility.
Primary Completion
August 2010
Actual (reported)Study Completion
August 2010
Actual (reported)Last Updated
December 20, 2010
Record last verified: 2010-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: